192 related articles for article (PubMed ID: 30092832)
21. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
22. Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time.
Chew GL; Huang D; Huo CW; Blick T; Hill P; Cawson J; Frazer H; Southey MD; Hopper JL; Henderson MA; Haviv I; Thompson EW
Breast Cancer Res Treat; 2013 Jul; 140(2):285-97. PubMed ID: 23881524
[TBL] [Abstract][Full Text] [Related]
23. Association between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort.
Makboon K; Gold EB; Harvey DJ; Butler LM; Habel LA
Cancer Causes Control; 2015 Mar; 26(3):431-42. PubMed ID: 25604866
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
Kotsopoulos J; Narod SA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):199-200. PubMed ID: 29308680
[No Abstract] [Full Text] [Related]
25. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
26. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Giannakeas V; Narod SA
Breast Cancer Res Treat; 2018 Jan; 167(1):263-267. PubMed ID: 28914396
[TBL] [Abstract][Full Text] [Related]
27. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
28. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
30. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
31. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
Yamauchi H; Okawa M; Yokoyama S; Nakagawa C; Yoshida R; Suzuki K; Nakamura S; Arai M
Breast Cancer Res Treat; 2018 Dec; 172(3):679-687. PubMed ID: 30203341
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
[TBL] [Abstract][Full Text] [Related]
33. Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
Vreemann S; Gubern-Mérida A; Schlooz-Vries MS; Bult P; van Gils CH; Hoogerbrugge N; Karssemeijer N; Mann RM
Radiology; 2018 Feb; 286(2):443-451. PubMed ID: 29040037
[TBL] [Abstract][Full Text] [Related]
34. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms.
Li H; Giger ML; Olopade OI; Margolis A; Lan L; Chinander MR
Acad Radiol; 2005 Jul; 12(7):863-73. PubMed ID: 16039540
[TBL] [Abstract][Full Text] [Related]
35. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
36. An overview of mammographic density and its association with breast cancer.
Nazari SS; Mukherjee P
Breast Cancer; 2018 May; 25(3):259-267. PubMed ID: 29651637
[TBL] [Abstract][Full Text] [Related]
37. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers.
Baltzer HL; Alonzo-Proulx O; Mainprize JG; Yaffe MJ; Metcalfe KA; Narod SA; Warner E; Semple JL
Ann Surg Oncol; 2014 May; 21(5):1583-8. PubMed ID: 24526546
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
39. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options].
Scheufler O; Fritschen Uv
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
